Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials

Current Cancer Drug Targets

Volumn 11, Issue 3, 2011, Pages 254-284

  Potts, B C ^a   Albitar, M X ^b   Anderson, K C ^c   Baritaki, S ^d   Berkers, C ^e   Bonavida, B ^d   Chandra, J ^f   Chauhan, D ^c   Cusack Jr , J C ^g   Fenical, W ^h   Ghobrial, I M ^c   Groll, M ⁱ   Jensen, P R ^h   Lam, K S ^a,j   Lloyd, G K ^a   Mcbride, W ^d   Mcconkey, D J ^f   Miller, C P ^f   Neuteboom, S T C ^a   Oki, Y ^f   Ovaa, H ^e   Pajonk, F ^d   Richardson, P G ^c   Roccaro, A M ^c   Sloss, C M ^g   Spear, M A ^a   Valashi, E ^d   Younes, A ^f   Palladino, M A ^a   more..

^a Nereus Pharmaceuticals Inc   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j Marrone Bio Innovations   (United States)

more..

Author keywords

Bortezomib; Combination therapy; Marizomib; Multiple myeloma; NF B; Pharmacodynamics; Proteasome inhibitor

Indexed keywords

BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; CARFILZOMIB; CEP 18770; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ENTINOSTAT; ERLOTINIB; FLUDARABINE; FLUDARABINE PHOSPHATE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; ISTODAX; LACTACYSTIN BETA LACTONE; LENALIDOMIDE; MLN 9708; ONX 0912; OXALIPLATIN; PROTEASOME INHIBITOR; RITUXIMAB; ROMIDEPSIN; SALINOSPORAMIDE A; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACTINOBACTERIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; AUTOPHAGY; BACKACHE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COLORECTAL CARCINOMA; CONJUGATION; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIZATION; DYSPNEA; ENZYME ACTIVATION; ENZYME ACTIVITY; FATIGUE; GLIOMA; HEADACHE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INJECTION SITE PAIN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; SALINISPORA TROPICA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; LACTONES; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLES;

EID: 79951684725     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911794519716     Document Type: Review

References (207)

1. Adams, J. Proteasome Inhibitors in Cancer Therapy. Humana Press, Totowa, NJ, 2004
2. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 2008, 14, 1649-1657
3. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67, 425-479
4. Palombella, V. J.; Rando, O. J.; Goldberg, A. L.; Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF- kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78, 773-785
5. Chauhan, D.; Uchiyama, H.; Akbarali, Y.; Urashima, M.; Yamamoto, K.; Libermann, T. A.; Anderson, K. C. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996, 87, 1104-1112
6. Russo, S. M.; Tepper, J. E.; Baldwin, A. S., Jr.; Liu, R.; Adams, J.; Elliott, P.; Cusack, J. C., Jr. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int. J. Rad. Onc. Biol. Phys. 2001, 50, 183-193
7. Adams, J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr. Opin. Chem. Biol. 2002, 6, 493-500
8. Hideshima, T.; Chauhan, D.; Richardson, P.; Mitsiades, C.; Mitsiades, N.; Hayashi, T.; Munshi, N.; Dong, L.; Castro, A.; Palombella, V.; Adams, J.; Anderson, K. C. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 2002, 277, 16639-16647
9. Kane, R. C.; Bross, P. F.; Farrell, A. T.; Pazdur, R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8, 508-513
10. Orlowski, R. Z.; Stinchcombe, T. E.; Mitchell, B. S.; Shea, T. C.; Baldwin, A. S.; Stahl, S.; Adams, J.; Esseltine, D. L.; Elliott, P. J.; Pien, C. S.; Guerciolini, R.; Anderson, J. K.; Depcik-Smith, N. D.; Bhagat, R.; Lehman, M. J.; Novick, S. C.; O'Connor, O. A.; Soignet, S. L. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002, 20, 4420-4427
11. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609-2617
12. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Irwin, D.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; San-Miguel, J. F.; Blade, J.; Boccadoro, M.; Cavenagh, J.; Dalton, W. S.; Boral, A. L.; Esseltine, D. L.; Porter, J. B.; Schenkein, D.; Anderson, K. C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2005, 352, 2487-2498
13. San Miguel, J. F.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M. T.; Palumbo, A.; Samoilova, O. S.; Dmoszynska, A.; Abdulkadyrov, K. M.; Schots, R.; Jiang, B.; Mateos, M. V.; Anderson, K. C.; Esseltine, D. L.; Liu, K.; Cakana, A.; van de Velde, H.; Richardson, P. G. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008, 359, 906-917
14. Fisher, R. I.; Bernstein, S. H.; Kahl, B. S.; Djulbegovic, B.; Robertson, M. J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J. P.; Lonial, S.; Stadtmauer, E. A.; O'Connor, O. A.; Shi, H.; Boral, A. L.; Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2006, 24, 4867-4874
15. Paoluzzi, L.; O'Connor, O. A. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 2006, 20, 13-23
16. Richardson, P. G.; Briemberg, H.; Jagannath, S.; Wen, P. Y.; Barlogie, B.; Berenson, J.; Singhal, S.; Siegel, D. S.; Irwin, D.; Schuster, M.; Srkalovic, G.; Alexanian, R.; Rajkumar, S. V.; Limentani, S.; Alsina, M.; Orlowski, R. Z.; Najarian, K.; Esseltine, D.; Anderson, K. C.; Amato, A. A. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 2006, 24, 3113-3120
17. Lonial, S.; Waller, E. K.; Richardson, P. G.; Jagannath, S.; Orlowski, R. Z.; Giver, C. R.; Jaye, D. L.; Francis, D.; Giusti, S.; Torre, C.; Barlogie, B.; Berenson, J. R.; Singhal, S.; Schenkein, D. P.; Esseltine, D. L.; Anderson, J.; Xiao, H.; Heffner, L. T.; Anderson, K. C. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005, 106, 3777-3784
18. Dick, L. R.; Fleming, P. E. Building on bortezomib: second- generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 2010, 15, 243-249
19. Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed. Engl. 2003, 42, 355-357.
20. Fenical, W.; Jensen, P. R.; Palladino, M. A.; Lam, K. S.; Lloyd, G. K.; Potts, B. C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 2009, 17, 2175-80
21. Lam, K. S.; Lloyd, G. K.; Neuteboom, S. T.; Palladino, M. A.; Sethna, K. M.; Spear, M. A.; Potts, B. C. From natural product to clinical trials: NPI-0052 (salinosporamide A), a marine actinomycete-derived anticancer agent. Royal Society of Chemistry: Cambridge, UK, 2010; Vol. Biomolecular Science, pp. 355-373.
22. Löwe, J.; Stock, D.; Jap, B.; Zwickl, P.; Baumeister, W.; Huber, R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995, 268, 533-539
23. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D.; Huber, R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997, 386, 463-471
24. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev. 2007, 107, 687-717
25. Groll, M.; Potts, B. C. Proteasome structure, function, and lessons learned from beta-lactone inhibitors. Curr. Top. Med. Chem., in press.
26. Fenteany, G.; Standaert, R. F.; Lane, W. S.; Choi, S.; Corey, E. J.; Schreiber, S. L. Inhibition of proteasome activities and subunit- specific amino-terminal threonine modification by lactacystin. Science 1995, 268, 726-731
27. Bull, A. T.; Stach, J. E. M. Marine actinobacteria: new opportunities for natural product search and discovery. Trends Microbiol. 2007, 15, 491-499
28. Maldonado, L. A.; Fenical, W.; Jensen, P. R.; Kauffman, C. A.; Mincer, T. J.; Ward, A. C.; Bull, A. T.; Goodfellow, M. Salinispora arenicola gen. nov., sp. nov. and Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family Micromonosporaceae. Int. J. Syst. Evol. Microbiol. 2005, 55, 1759-1766.
29. Mincer, T.; Jensen, P.; Kauffman, C.; Fenical, W. Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments. Appl. Environ. Microbiol. 2002, 68, 5005-5011
30. Fenical, W.; Jensen, P. R. Developing a new resource for drug discovery: marine actinomycete bacteria. Nat. Chem. Biol. 2006, 2, 666-673
31. Udwary, D.; Zeigler, L.; Asolkar, R.; Singan, V.; Lapidus, A.; Fenical, W.; Jensen, P.; Moore, B. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc. Natl. Acad. Sci. U S A 2007, 104, 10376-10381
32. Eustaquio, A. S.; Pojer, F.; Noe, J. P.; Moore, B. S. Discovery and characterization of a marine bacterial SAM-dependent chlorinase. Nat. Chem. Biol. 2008, 4, 69-74
33. Eustaquio, A. S.; McGlinchey, R. P.; Liu, Y.; Hazzard, C.; Beer, L. L.; Florova, G.; Alhamadsheh, M. M.; Lechner, A.; Kale, A. J.; Kobayashi, Y.; Reynolds, K. A.; Moore, B. S. Biosynthesis of the salinosporamide A polyketide synthase substrate chloroethyl- malonyl-coenzyme A from S-adenosyl-L-methionine. Proc. Natl. Acad. Sci. USA 2009, 106, 12295-12300
34. Shah, I. M.; Lees, K. R.; Pien, C. P.; Elliott, P. J. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 2002, 54, 269-276
35. Macherla, V. R.; Mitchell, S. S.; Manam, R. R.; Reed, K. A.; Chao, T. H.; Nicholson, B.; Deyanat-Yazdi, G.; Mai, B.; Jensen, P. R.; Fenical, W. F.; Neuteboom, S. T.; Lam, K. S.; Palladino, M. A.; Potts, B. C. Structure-activity relationship studies of salino- sporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J. Med. Chem. 2005, 48, 3684-3687
36. Potts, B. C.; Lam, K. S. Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (NPI-0052) and other salinosporamides. Mar. Drugs 2010 8, 835-880
37. Nett, M.; Gulder, T. A.; Kale, A. J.; Hughes, C. C.; Moore, B. S. Function-oriented biosynthesis of beta-lactone proteasome inhi- bitors in Salinispora tropica. J. Med. Chem. 2009, 52, 6163-6167
38. Manam, R. R.; McArthur, K. A.; Chao, T. H.; Weiss, J.; Ali, J. A.; Palombella, V. J.; Groll, M.; Lloyd, G. K.; Palladino, M. A.; Neuteboom, S. T.; Macherla, V. R.; Potts, B. C. Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. J. Med. Chem. 2008, 51, 6711-6724
39. Williams, P. G.; Buchanan, G. O.; Feling, R. H.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica. J. Org. Chem. 2005, 70, 6196-6203
40. Manam, R. R.; Macherla, V. R.; Tsueng, G.; Dring, C. W.; Weiss, J.; Neuteboom, S. T.; Lam, K. S.; Potts, B. C. Antiprotealide is a natural product. J. Nat. Prod. 2009, 72, 295-297
41. Potts, B. C.; Macherla, V. R.; Mitchell, S. S.; Manam, R. R.; Reed, K. A.; Lam, K. S.; Neuteboom, S. T. C.; Chao, T.-H.; Nicholson, B.; Billstrom, C [3.2.0] Heterocyclic compounds and methods of using the same. WO 2006/028525 A2 2006
42. McGlinchey, R. P.; Nett, M.; Eustaquio, A. S.; Asolkar, R. N.; Fenical, W.; Moore, B. S. Engineered biosynthesis of antiprotealide and other unnatural salinosporamide proteasome inhibitors. J. Am. Chem. Soc. 2008, 130, 7822-7823
43. Macherla, V. R.; Potts, B. C.; Manam, R. R.; McArthur, K. A.; Chao, T.-H.; Neuteboom, S. T. C. Proteasome inhibitors. US 2009/0298906 A1 2009
44. Reddy, L. R.; Fournier, J. F.; Reddy, B. V. S.; Corey, E. J. An efficient, stereocontrolled synthesis of a potent omuralide- salinosporin hybrid for selective proteasome inhibition. J. Am. Chem. Soc. 2005, 127, 8974-8976
45. Reed, K. A.; Manam, R. R.; Mitchell, S. S.; Xu, J.; Teisan, S.; Chao, T. H.; Deyanat-Yazdi, G.; Neuteboom, S. T.; Lam, K. S.; Potts, B. C. Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome. J. Nat. Prod. 2007, 70, 269-276
46. Ling, T.; Potts, B. C.; Macherla, V. R. Concise formal synthesis of (-)-salinosporamide a (marizomib) using a regio- and stereoselective epoxidation and reductive oxirane ring opening strategy. J. Org. Chem. 2010 75, 3882-3885
47. Tsueng, G.; Teisan, S.; Lam, K. S. Defined salt formulations for the growth of Salinispora tropica strain NPS21184 and the production of salinosporamide A (NPI-0052) and related analogs. Appl. Microbiol. Biotechnol. 2008, 78, 827-832
48. Tsueng, G.; Lam, K. S. Stabilization effect of resin on the production of potent proteasome inhibitor NPI-0052 during submerged fermentation of Salinispora tropica. J. Antibiot. 2007, 60, 469-472
49. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T. H.; Neuteboom, S. T.; Richardson, P.; Palladino, M. A.; Anderson, K. C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005, 8, 407-419
50. Groll, M.; Huber, R.; Potts, B. C. Crystal Structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 2006, 128, 5136-5141
51. Dick, L. R.; Cruikshank, A. A.; Grenier, L.; Melandri, F. D.; Nunes, S. L.; Stein, R. L. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J. Biol. Chem. 1996, 271, 7273-7276
52. Singh, A. V.; Palladino, M. A.; Lloyd, G. K.; Potts, B. C.; Chauhan, D.; Anderson, K. C. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br. J. Haematol. 2010, 149, 550-559
53. Chao, T.-H.; Wahlgren, B.; Obaidat, A.; Weiss, J.; Manam, R. R.; McArthur, K. A.; Macherla, V. R.; Palladino, M. A.; Hagenbuch, B.; Potts, B. C.; Enna, S. J.; Lloyd, G. K.; Neuteboom, S. T. C., The chlorine leaving group of the proteasome inhibitor NPI-0052 is key to its potency, durability of proteasome inhibition and may in- fluence its efflux rate from tumor cells. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research 2009, 4539
54. Groll, M.; Kim, K. B.; Kairies, N.; Huber, R.; Crews, C. M. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha ',beta '-epoxyketone proteasome inhibitors. J. Am. Chem. Soc. 2000, 122, 1237-1238
55. Groll, M.; Berkers, C. R.; Ploegh, H. L.; Ovaa, H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006, 14, 451-456
56. Parlati, F.; Lee, S. J.; Aujay, M.; Suzuki, E.; Levitsky, K.; Lorens, J. B.; Micklem, D. R.; Ruurs, P.; Sylvain, C.; Lu, Y.; Shenk, K. D.; Bennett, M. K. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009, 114, 3439-3447
57. Ruiz, S.; Krupnik, Y.; Keating, M.; Chandra, J.; Palladino, M.; McConkey, D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol. Cancer Ther. 2006, 5, 1836-1843
58. Hale, R.; Miller, C.; Manam, R. R.; Macherla, V. R.; Palladino, M.; Potts, B.; Chandra, J. Reactive oxygen species (ROS) generation and caspase-8 activation by analogs of proteasome inhibitor NPI- 0052. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research 2009, 5634
59. Townsend, A. R.; Millward, M.; Price, T.; Mainwaring, P.; Spencer, A.; Longenecker, A. Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J. Clin. Oncol. 2009, 27:15s #3582
60. Demo, S. D.; Kirk, C. J.; Aujay, M. A.; Buchholz, T. J.; Dajee, M.; Ho, M. N.; Jiang, J.; Laidig, G. J.; Lewis, E. R.; Parlati, F.; Shenk, K. D.; Smyth, M. S.; Sun, C. M.; Vallone, M. K.; Woo, T. M.; Molineaux, C. J.; Bennett, M. K. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007, 67, 6383-6391
61. Palladino, M. A.; Chao, T.; Neuteboom, S. T.; Spear, M.; Ma, W.; Albitar, M. Preclinical and clinical monitoring of cell-and circulating plasma specific proteasome biomarkers after treatment with the proteasome inhibitor NPI-0052. Eur. J. Cancer Suppl. 2008, 6, 235
62. Ma, W.; Kantarjian, H.; Bekele, B.; Donahue, A. C.; Zhang, X.; Zhang, Z. J.; O'Brien, S.; Estey, E.; Estrov, Z.; Cortes, J.; Keating, M.; Giles, F.; Albitar, M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin. Cancer Res. 2009, 15, 3820-3826
63. Jakob, C.; Egerer, K.; Liebisch, P.; Türkmen, S.; Zavrski, I.; Kuckelkorn, U.; Heider, U.; Kaiser, M.; Fleissner, C.; Sterz, J.; Kleeberg, L.; Feist, E.; Burmester, G. R.; Kloetzel, P. M.; Sezer, O. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007, 109, 2100-2105
64. Kisselev, A. F.; Callard, A.; Goldberg, A. L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem. 2006, 281, 8582-8590
65. Ahn, K. S.; Sethi, G.; Chao, T. H.; Neuteboom, S. T. C.; Chaturvedi, M. M.; Palladino, M. A.; Younes, A.; Aggarwal, B. B. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis and inhibits invasion through down-regulation of NF- B-regulated gene products. Blood 2007, 110, 2286-2295
66. Anderson, K. C. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp. Hematol. 2007, 35, 155-162
67. Chauhan, D.; Hideshima, T.; Anderson, K. C. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu. Rev. Pharm. Tox. 2005, 45, 4655-4476
68. Chauhan, D.; Li, G.; Shringarpure, R.; Podar, K.; Ohtake, Y.; Hideshima, T.; Anderson, K. C. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003, 63, 6174-6177
69. Zhu, K.; Chan, W.; Heymach, J.; Wilkinson, M.; McConkey, D. J. Control of HIF-1alpha expression by eIF2 alpha phosphorylation- mediated translational repression. Cancer Res. 2009, 69, 1836-1843
70. LeBlanc, R.; Catley, L. P.; Hideshima, T.; Lentzsch, S.; Mitsiades, C. S.; Mitsiades, N.; Neuberg, D.; Goloubeva, O.; Pien, C. S.; Adams, J.; Gupta, D.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62, 4996-5000
71. Chauhan, D.; Singh, A.; Brahmandam, M.; Podar, K.; Hideshima, T.; Richardson, P.; Munshi, N.; Palladino, M. A.; Anderson, K. C. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111, 1654-1664
72. Roccaro, A. M.; Leleu, X.; Sacco, A.; Jia, X.; Melhem, M.; Moreau, A. S.; Ngo, H. T.; Runnels, J.; Azab, A.; Azab, F.; Burwick, N.; Farag, M.; Treon, S. P.; Palladino, M. A.; Hideshima, T.; Chauhan, D.; Anderson, K. C.; Ghobrial, I. M. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008, 111, 4752-4763
73. Richardson, P.; Lonial, S.; Jakubowiak, A. J.; Jagannath, S. Lenalidomide, Bortezomib, and Dexamethasone in patients with newly diagnosed multiple myeloma: Encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood 2008, 112, 92
74. Richardson, P.; Jagannath, S.; Jakubowiak, A. J.; Lonial, S. Lenalidomide, Bortezomib, and Dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma: Encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood 2008, 112, 1742
75. [75] Kim, K.; Kong, S. Y.; Fulciniti, M.; Li, X.; Song, W.; Nahar, S.; Burger, P.; Rumizen, M. J.; Podar, K.; Chauhan, D.; Hideshima, T.; Munshi, N. C.; Richardson, P.; Clark, A.; Ogden, J.; Goutopoulos, A.; Rastelli, L.; Anderson, K. C.; Tai, Y. T. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br. J. Haematol. 2010, [Epub a head of print]
76. Adams, J. The proteasome: structure, function, and role in the cell. Cancer Treat. Rev. 2003, 29, 3-9
77. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5, 417-421
78. Panwalkar, A.; Verstovsek, S.; Giles, F. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer Biol. Ther. 2004, 100, 1578-1589
79. Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441, 431-436
80. Hatzimichael, E. C.; Christou, L.; Bai, M.; Kolios, G.; Kefala, L.; Bourantas, K. L. Serum levels of IL-6 and its soluble receptor (sIL- 6R) in Waldenstrom's macroglobulinemia. Eur. J. Haematol. 2001, 66, 1-6
81. Treon, S. P.; Hunter, Z. R.; Matous, J. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglo- bulinemia: results of WMCTG trial 03-248. Clin. Cancer Res. 2007, 13, 3320-3325
82. Ahn, K. S.; Sethi, G.; Aggarwal, B. B. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol. Pharmacol. 2007, 71, 209-219
83. Miller, C. P.; Ban, K.; Dujka, M. E.; McConkey, D. J.; Munsell, M.; Palladino, M.; Chandra, J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110, 267-277
84. Keating, M. J.; Chiorazzi, N.; Messmer, B.; Damle, R. N.; Allen, S. L.; Rai, K. R.; Ferrarini, M.; Kipps, T. J. Biology and Treatment of Chronic Lymphocytic Leukemia. Hematology 2003, 2003, 153-175
85. Chiorazzi, N.; Rai, K. R.; Ferrarini, M. Mechanisms of disease: chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 352, 804-815
86. Hanada, M.; Delia, D.; Aiello, A.; Stadtmauer, E.; Reed, J. C. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82, 1820-1828
87. Czuczman, M. S.; Gregory, S. A. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk. Lymphoma 2010, Epub, April 2010
88. Lundin, J.; Kimby, E.; Bjorkholm, M.; Broliden, P.-A.; Celsing, F.; Hjalmar, V.; Mollgard, L.; Rebello, P.; Hale, G.; Walderman, H.; Mellstedt, H.; Osterborg, A. Phase II trials of subcutaneous anti- CD52 monoclonal antibody alemtuzumab (Campath-1H) as first- line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100, 768-773
89. Duechler, M.; Linke, A.; Cebula, B.; Shehata, M.; Schwarzmeier, J. D.; Robak, T.; Smolewski, P. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur. J. Haematol. 2005, 74, 407-417
90. Pahler, J. C.; Ruiz, S.; Calvert, L. R.; Andreeff, M.; Keating, M.; Faderl, S.; McConkey, D. J. Proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin. Cancer Res. 2003, 9, 4570-4577
91. Faderl, S.; Rai, K.; Gribben, J.; Byrd, J. C.; Flinn, I. W.; O'Brien, S.; Sheng, S.; Esseltine, D.-L.; Keating, M. J. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006, 107, 916-924
92. Liu, F.-T.; Agrawal, S. G.; Movasaghi, Z.; Wyatt, P. B.; Rahman, I. U.; Gribben, J. G.; Newland, A. C.; Jia, L. Dietary flavonoids inhibit the anticancer effects of proteasome inhibitor bortezomib. Blood 2008, 112, 3835-3846
93. Golden, E. B.; Lam, P. Y.; Kardosh, A.; Gaffney, K. J.; Cadenas, E.; Louie, S. G.; Petasis, N. A.; Chen, T. C.; Schonthal, A. H. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113, 5927-5937
94. Kim, T. Y.; Park, J.; Oh, B.; Min, H. J.; Jeong, T. S.; Lee, J. H.; Suh, C.; Cheong, J. W.; Kim, H. J.; Yoon, S. S.; Park, S. B.; Lee, D. S. Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction. Br. J. Haematol. 2009, 146, 270-281
95. Cortes, J. E.; Kantarjian, H. M. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer 1995, 76, 2393-2417
96. Haddy, T. B.; Mosher, R. B.; Reaman, G. H. Late effects in long- term survivors after treatment for childhood acute leukemia. Clin. Pediatr. (Phila) 2009, 48, 601-608
97. Yang, H.; Zonder, J. A.; Dou, Q. P. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin. Investig. Drugs 2009, 18, 957-971
98. Cortes, J.; Thomas, D.; Koller, C.; Giles, F.; Estey, E.; Faderl, S.; Garcia-Manero, G.; McConkey, D.; Ruiz, S. L.; Guerciolini, R.; Wright, J.; Kantarjian, H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 2004, 10, 3371-3376
99. Lewis, B. J.; DeVita, V. T., Jr. Combination chemotherapy of acute leukemia and lymphoma. Pharmacol. Ther. 1979, 7, 91-121
100. O'Connor, O. A. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin. Lymphoma Myeloma 2005, 6, 191-199
101. O'Connor, O. A.; Smith, E. A.; Toner, L. E.; Teruya-Feldstein, J.; Frankel, S.; Rolfe, M.; Wei, X.; Liu, S.; Marcucci, G.; Chan, K. K.; Chanan-Khan, A. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006, 12, 2902-2911
102. Marks, P. A.; Xu, W. S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell Biochem. 2009, 107, 600-608
103. Dai, Y.; Chen, S.; Kramer, L. B.; Funk, V. L.; Dent, P.; Grant, S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin. Cancer Res. 2008, 14, 549-58
104. Miller, C. P.; Rudra, S.; Keating, M. J.; Wierda, W. G.; Palladino, M.; Chandra, J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009, 113, 4289-4299
105. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 122, 27-55
106. Buglio, D.; Mamidipudi, V.; Khaskhely, N. M.; Gloghanni, A.; Carbone, A.; Heise, C.; Besterman, J. M.; Martelli, R. E.; MacBeth, K. J.; Younes, A. The histone deacetylase inhibitor MGCD0103 down regulates CD30. Activates NF-kB and synergizes with proteasome inhibitors by HDAC6 independent mechanism in Hodgkin lymphoma. Blood 2009, 114, 3735
107. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L.; Rehman, M.; Walther, T. C.; Olsen, J. V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325, 834-840
108. Place, R. F.; Noonan, E. J.; Giardina, C. HDAC inhibition prevents NF-kB activation by suppressing proteasome activity: down regulation of proteasome subunit expression stabilizes IkBa. Biochem. Pharmacol. 2005, 70, 394-406
109. Goy, A.; Younes, A.; McLaughlin, P.; Pro, B.; Romaguera, J. E.; Hagemeister, F.; Fayad, L.; Dang, N. H.; Samaniego, F.; Wang, M.; Broglio, K.; Samuels, B.; Gilles, F.; Sarris, A. H.; Hart, S.; Trehu, E.; Schenkein, D.; Cabanillas, F.; Rodriguez, A. M. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncology 2005, 23, 667-675
110. O'Connor, O. A.; Wright, J.; Moskowitz, C.; Muzzy, J.; MacGregor-Cortelli, B.; Stubblefield, M.; Straus, D.; Portlock, C.; Hamlin, P.; Choi, E.; Dumetrescu, O.; Trehu, E.; Adams, J.; Schenkein, D.; Zelenetz, A. D. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncology 2005, 23, 676-684
111. Kane, R. C.; Dagher, R.; Farrell, A. T.; Ko, C.-W.; Sridhara, R. M.; Pazdur, R. Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 2007, 13, 5291-5294
112. Buglio, D.; Georgios, G.; Chao, T.-H.; Neuteboom, S.; Palladino, M.; A novel proteasome inhibitor, NPI-0052 is active in Hodgkin and Mantle cell lymphoma cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 2007, 1454
113. Yazbeck, V. Y.; Georgakis, G. V.; Li, Y.; McConkey, D.; Andreeff, M.; Younes, A. Inhibition of the pan-Bcl-2 family by the small molecule GX15-070 induces apoptosis in mantle cell lymphoma (MCL) cells and enhances the activity of two proteasome inhibitors (NPI-0052 and bortezomib), and doxorubicin chemotherapy. Blood 2006, 108, 253
114. Lieu, C.; Chow, L.; Pierson, A. S.; Eckhardt, S. G.; O'Bryant, C. L.; Morrow, M.; Tran, Z. V.; Wright, J. J.; Gore, L. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest. New Drugs 2009, 27, 53-62
115. Pugh, T. J.; Chen, C.; Rabinovitch, R.; Eckhardt, S. G.; Rusthoven, K. E.; Swing, R.; Raben, D. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int. J. Rad. Onc. Biol. Phys. 2010 Epub 2010/02/06
116. Kubicek, G. J.; Werner-Wasik, M.; Machtay, M.; Mallon, G.; Myers, T.; Ramirez, M.; Andrews, D.; Curran, W. J., Jr.; Dicker, A. P. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys. 2008, 74, 433-439
117. Kojima, M.; Morisaki, T.; Sasaki, N.; Nakano, K.; Mibu, R.; Tanaka, M.; Katano, M. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res. 2004, 24, 675-681
118. Cusack, J. C., Jr.; Liu, R.; Baldwin, A. S., Jr. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]- carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor- kappaB activation. Cancer Res. 2000, 60, 2323-2330
119. Voboril, R.; Hochwald, S. N.; Li, J.; Brank, A.; Weberova, J.; Wessels, F.; Moldawer, L. L.; Camp, E. R.; MacKay, S. L. Inhibition of NF-kappa B augments sensitivity to 5- fluorouracil/folinic acid in colon cancer. J. Surg. Res. 2004, 120, 178-188
120. Cusack, J. C., Jr.; Liu, R.; Xia, L.; Chao, T. H.; Pien, C.; Niu, W.; Palombella, V. J.; Neuteboom, S. T.; Palladino, M. A. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin. Cancer Res. 2006, 12, 6758-6764
121. Ding, W. X.; Ni, H. M.; Chen, X.; Yu, J.; Zhang, L.; Yin, X. M. A coordinated action of Bax, PUMA, and p53 promotes MG132- induced mitochondria activation and apoptosis in colon cancer cells. Mol. Cancer Ther. 2007, 6, 1062-1069
122. Loeffler-Ragg, J.; Mueller, D.; Gamerith, G.; Auer, T.; Skvortsov, S.; Sarg, B.; Skvortsova, I.; Schmitz, K. J.; Martin, H. J.; Krugmann, J.; Alakus, H.; Maser, E.; Menzel, J.; Hilbe, W.; Lindner, H.; Schmid, K. W.; Zwierzina, H. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol. Cancer Ther. 2009, 8, 1995-2006
123. Uddin, S.; Ahmed, M.; Bavi, P.; El-Sayed, R.; Al-Sanea, N.; AbdulJabbar, A.; Ashari, L. H.; Alhomoud, S.; Al-Dayel, F.; Hussain, A. R.; Al-Kuraya, K. S. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res. 2008, 68, 3379-3388
124. Yu, J.; Tiwari, S.; Steiner, P.; Zhang, L. Differential apoptotic response to the proteasome inhibitor bortezomib [VELCADE, PS- 341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol. Ther. 2003, 2, 694-699
125. Pitts, T. M.; Morrow, M.; Kaufman, S. A.; Tentler, J. J.; Eckhardt, S. G. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol. Cancer Ther. 2009, 8, 342-349
126. Okumura, K.; Huang, S.; Sinicrope, F. A. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin. Cancer Res. 2008, 14, 8132-3142
127. Nowis, D.; McConnell, E. J.; Dierlam, L.; Palamarchuk, A.; Lass, A.; Wojcik, C. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. Int. J. Cancer 2007, 121, 431-441
128. Mackay, H.; Hedley, D.; Major, P.; Townsley, C.; Mackenzie, M.; Vincent, M.; Degendorfer, P.; Tsao, M. S.; Nicklee, T.; Birle, D.; Wright, J.; Siu, L.; Moore, M.; Oza, A. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin. Cancer Res. 2005, 11, 5526-5533
129. Kozuch, P. S.; Rocha-Lima, C. M.; Dragovich, T.; Hochster, H.; O'Neil, B. H.; Atiq, O. T.; Pipas, J. M.; Ryan, D. P.; Lenz, H. J. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J. Clin. Oncol. 2008, 26, 2320-2326
130. Caponigro, F.; Lacombe, D.; Twelves, C.; Bauer, J.; Govaerts, A. S.; Marreaud, S.; Milano, A.; Anthoney, A. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur. J. Cancer 2009, 45, 48-55
131. Sloss, C. M.; Wang, F.; Liu, R.; Xia, L.; Houston, M.; Ljungman, D.; Palladino, M. A.; Cusack, J. C., Jr. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR- independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 2008, 14, 5116-5123
132. Sloss, C. M.; Wang, F.; Palladino, M. A.; Cusack, J. C., Jr. Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells. Oncogene 2010, 29, 3146-3152
133. Nawrocki, S. T.; Bruns, C. J.; Harbison, M. T.; Bold, R. J.; Gotsch, B. S.; Abbruzzese, J. L.; Elliott, P.; Adams, J.; McConkey, D. J. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 2002, 1, 1243-1253
134. Shah, S. A.; Potter, M. W.; McDade, T. P.; Ricciardi, R.; Perugini, R. A.; Elliott, P. J.; Adams, J.; Callery, M. P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 2001, 82, 110-122
135. Bold, R. J.; Virudachalam, S.; McConkey, D. J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 2001, 100, 11-17
136. Chandler, N. M.; Canete, J. J.; Callery, M. P. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J. Gastrointest. Surg. 2004, 8, 1072-1078
137. Nawrocki, S. T.; Sweeney-Gotsch, B.; Takamori, R.; McConkey, D. J. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 2004, 3, 59-70
138. Bai, J.; Demirjian, A.; Sui, J.; Marasco, W.; Callery, M. P. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS- 341 synergistically induce apoptosis in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2006, 348, 1245-1253
139. Khanbolooki, S.; Nawrocki, S. T.; Arumugam, T.; Andtbacka, R.; Pino, M. S.; Kurzrock, R.; Logsdon, C. D.; Abbruzzese, J. L.; McConkey, D. J. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 2006, 5, 2251-2260
140. Nawrocki, S. T.; Carew, J. S.; Pino, M. S.; Highshaw, R. A.; Andtbacka, R. H.; Dunner, K., Jr.; Pal, A.; Bornmann, W. G.; Chiao, P. J.; Huang, P.; Xiong, H.; Abbruzzese, J. L.; McConkey, D. J. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006, 66, 3773-2781
141. Shi, Y. Y.; Small, G. W.; Orlowski, R. Z. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res. Treat. 2006, 100, 33-47
142. Small, G. W.; Shi, Y. Y.; Edmund, N. A.; Somasundaram, S.; Moore, D. T.; Orlowski, R. Z. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol. Pharmacol. 2004, 66, 1478-1490
143. Hideshima, T.; Podar, K.; Chauhan, D.; Ishitsuka, K.; Mitsiades, C.; Tai, Y. T.; Hamasaki, M.; Raje, N.; Hideshima, H.; Schreiner, G.; Nguyen, A. N.; Navas, T.; Munshi, N. C.; Richardson, P. G.; Higgins, L. S.; Anderson, K. C. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004, 23, 8766-8776
144. Meriin, A. B.; Gabai, V. L.; Yaglom, J.; Shifrin, V. I.; Sherman, M. Y. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J. Biol. Chem. 1998, 273, 6373-9
145. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T. A.; Treon, S. P.; Munshi, N. C.; Richardson, P. G.; Hideshima, T.; Anderson, K. C. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 2002, 99, 14374-14379
146. Robertson, J. D.; Datta, K.; Biswal, S. S.; Kehrer, J. P. Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor- induced apoptosis. Biochem. J. 1999, 344 Pt 2, 477-485
147. Papandreou, C. N.; Daliani, D. D.; Nix, D.; Yang, H.; Madden, T.; Wang, X.; Pien, C. S.; Millikan, R. E.; Tu, S. M.; Pagliaro, L.; Kim, J.; Adams, J.; Elliott, P.; Esseltine, D.; Petrusich, A.; Dieringer, P.; Perez, C.; Logothetis, C. J. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 2004, 22, 2108-2121
148. Dudek, A. Z.; Lesniewski-Kmak, K.; Shehadeh, N. J.; Pandey, O. N.; Franklin, M.; Kratzke, R. A.; Greeno, E. W.; Kumar, P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Brit. J. Cancer 2009, 100, 1379-1384
149. Ryan, D. P.; Appleman, L. J.; Lynch, T.; Supko, J. G.; Fidias, P.; Clark, J. W.; Fishman, M.; Zhu, A. X.; Enzinger, P. C.; Kashala, O.; Cusack, J., Jr.; Eder, J. P. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 2006, 107, 2482-2489
150. Ryan, D. P.; O'Neil, B. H.; Supko, J. G.; Rocha Lima, C. M.; Dees, E. C.; Appleman, L. J.; Clark, J.; Fidias, P.; Orlowski, R. Z.; Kashala, O.; Eder, J. P.; Cusack, J. C., Jr. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006, 107, 2688-2697
151. Alberts, S. R.; Foster, N. R.; Morton, R. F.; Kugler, J.; Schaefer, P.; Wiesenfeld, M.; Fitch, T. R.; Steen, P.; Kim, G. P.; Gill, S. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann. Oncol. 2005, 16, 1654-1661
152. Arumugam, T.; Ramachandran, V.; Fournier, K. F.; Wang, H.; Marquis, L.; Abbruzzese, J. L.; Gallick, G. E.; Logsdon, C. D.; McConkey, D. J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69, 5820-5828
153. Papageorgiou, A.; Kamat, A.; Benedict, W. F.; Dinney, C.; McConkey, D. J. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol. Cancer Ther. 2006, 5, 3032-3041
154. Sunwoo, J. B.; Chen, Z.; Dong, G.; Yeh, N.; Crowl Bancroft, C.; Sausville, E.; Adams, J.; Elliott, P.; Van Waes, C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor- kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 2001, 7, 1419-1428
155. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732
156. Kaluz, S.; Kaluzova, M.; Stanbridge, E. J. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol. Cell Biol. 2006, 26, 5895-5907
157. Birle, D. C.; Hedley, D. W. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res. 2007, 67, 1735-1743
158. Hudes, G. R.; Berkenblit, A.; Feingold, J.; Atkins, M. B.; Rini, B. I.; Dutcher, J. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin. Oncol. 2009, 36 Suppl 3, S26-36
159. Olive, K. P.; Jacobetz, M. A.; Davidson, C. J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgraben, M. A.; Caldwell, M. E.; Allard, D.; Frese, K. K.; Denicola, G.; Feig, C.; Combs, C.; Winter, S. P.; Ireland-Zecchini, H.; Reichelt, S.; Howat, W. J.; Chang, A.; Dhara, M.; Wang, L.; Ruckert, F.; Grutzmann, R.; Pilarsky, C.; Izeradjene, K.; Hingorani, S. R.; Huang, P.; Davies, S. E.; Plunkett, W.; Egorin, M.; Hruban, R. H.; Whitebread, N.; McGovern, K.; Adams, J.; Iacobuzio-Donahue, C.; Griffiths, J.; Tuveson, D. A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324, 1457-1461
160. Cartwright, T.; Richards, D. A.; Boehm, K. A. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 2008, 15, 308-313
161. Kaelin, W. G., Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009, 115, 2262-2272
162. Zhu, K.; Dunner, K., Jr.; McConkey, D. J. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 29, 451-462
163. Amaravadi, R. K.; Thompson, C. B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res. 2007, 13, 7271-7279
164. Lum, J. J.; DeBerardinis, R. J.; Thompson, C. B. Autophagy in metazoans: cell survival in the land of plenty. Nat. Rev. Mol. Cell Biol. 2005, 6, 439-448
165. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996
166. Yin, D.; Zhou, H.; Kumagai, T.; Liu, G.; Ong, J. M.; Black, K. L.; Koeffler, H. P. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005, 24, 344-354
167. Vlashi, E.; Mattes, M.; Lagadec, C.; Donna, L. D.; Phillips, T. M.; Nikolay, P.; McBride, W. H.; Pajonk, F. Differential effects of the proteasome inhibitor NPI-0052 against glioma cells. Transl. Oncol. 2010, 3, 50-55
168. Pedeboscq, S.; L'Azou, B.; Passagne, I.; De Giorgi, F.; Ichas, F.; Pometan, J. P.; Cambar, J. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. J. Exp. Ther. Oncol. 2008, 7, 99-111
169. Labussiere, M.; Pinel, S.; Delfortrie, S.; Plenat, F.; Chastagner, P. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts. Oncol. Rep. 2008, 20, 1283-1287
170. Phuphanich, S.; Supko, J. G.; Carson, K. A.; Grossman, S. A.; Burt Nabors, L.; Mikkelsen, T.; Lesser, G.; Rosenfeld, S.; Desideri, S.; Olson, J. J. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J. Neurooncol. 2010 Epub 2010 Mar 8
171. Zunkeler, B.; Carson, R. E.; Olson, J.; Blasberg, R. G.; DeVroom, H.; Lutz, R. J.; Saris, S. C.; Wright, D. C.; Kammerer, W.; Patronas, N. J.; Dedrick, R. L.; Herscovitch, P.; Oldfield, E. H. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J. Neurosurg. 1996, 85, 1056-1065
172. Pajonk, F.; van Ophoven, A.; Weissenberger, C.; McBride, W. H. The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer 2005, 5, 76
173. Vlashi, E.; Kim, K.; Dealla Donna, L.; Lagadec, C.; McDonald, T.; Eghbali, M.; Sayre, J.; Stefani, E.; McBride, W.; Pajonk, F. In-vivo imaging, tracking, and targeting of cancer stem cells. J. Natl. Cancer Inst. 2009, 101, 350-359
174. Mortenson, M. M.; Schlieman, M. G.; Virudachalam, S.; Bold, R. J. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother. Pharmacol. 2004, 54, 343-353
175. Pajonk, F.; Grumann, T.; McBride, W. H. The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation. Neoplasia 2006, 8, 1037-1041
176. Giamas, G.; Man, Y. L.; Hirner, H.; Bischof, J.; Kramer, K.; Khan, K.; Lavina Ahmed, S. S.; Stebbing, J.; Knippschild, U. Kinases as targets in the treatment of solid tumors. Cell. Signal. 2010, 22, 984-1002
177. Sheikh, M. S.; Fornace, A. J., Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000, 14, 1509-1513
178. Wang, S.; El-Deiry, W. S. TRAIL and apoptosis induction by TNF- family death receptors. Oncogene 2003, 22, 8628-8633
179. Yagita, H.; Takeda, K.; Hayakawa, Y.; Smyth, M. J.; Okumura, K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004, 95, 777-783
180. Wang, H.; Hertlein, E.; Bakkar, N.; Sun, H.; Acharyya, S.; Wang, J.; Carathers, M.; Davuluri, R.; Guttridge, D. C. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol. Cell Biol. 2007, 27, 4374-4387
181. Baritaki, S.; Huerta-Yepez, S.; Sakai, T.; Spandidos, D. A.; Bonavida, B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol. Cancer Ther. 2007, 6, 1387-1399
182. Baritaki, S.; Suzuki, E.; Umezawa, K.; Spandidos, D. A.; Berenson, J.; Daniels, T. R.; Penichet, M. L.; Jazirehi, A. R.; Palladino, M.; Bonavida, B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J. Immunol. 2008, 180, 6199-6210
183. Yeung, K.; Seitz, T.; Li, S.; Janosch, P.; McFerran, B.; Kaiser, C.; Fee, F.; Katsanakis, K. D.; Rose, D. W.; Mischak, H.; Sedivy, J. M.; Kolch, W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999, 401, 173-177
184. Yeung, K. C.; Rose, D. W.; Dhillon, A. S.; Yaros, D.; Gustafsson, M.; Chatterjee, D.; McFerran, B.; Wyche, J.; Kolch, W.; Sedivy, J. M. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol. Cell Biol. 2001, 21, 7207-7217
185. Beach, S.; Tang, H.; Park, S.; Dhillon, A. S.; Keller, E. T.; Kolch, W.; Yeung, K. C. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 2008, 27, 2243-2248
186. Julien, S.; Puig, I.; Caretti, E.; Bonaventure, J.; Nelles, L.; van Roy, F.; Dargemont, C.; de Herreros, A. G.; Bellacosa, A.; Larue, L. Activation of NF-kappaB by Akt upregulates snail expression and induces epithelium mesenchyme transition. Oncogene 2007, 26, 7445-7456
187. Baritaki, S.; Katsman, A.; Chatterjee, D.; Yeung, K. C.; Spandidos, D. A.; Bonavida, B. Regulation of tumor cell sensitivity to TRAIL- induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up- regulation. J. Immunol. 2007, 179, 5441-5453
188. Baritaki, S.; Yeung, K.; Palladino, M.; Berenson, J.; Bonavida, B. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmun- osensitization. Cancer Res. 2009, 69, 8376-8385
189. Lightcap, E. S.; McCormack, T. A.; Pien, C. S.; Chau, V.; Adams, J.; Elliott, P. J. Proteasome inhibition measurements: clinical application. Clin. Chem. 2000, 46, 673-683
190. Berkers, C. R.; Verdoes, M.; Lichtman, E.; Fiebiger, E.; Kessler, B. M.; Anderson, K. C.; Ploegh, H. L.; Ovaa, H.; Galardy, P. J. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat. Methods 2005, 2, 357-362
191. Berkers, C.; van Leeuwen, F. W. B.; Groothuis, T. A.; Peperzak, V.; van Tilburg, E. W.; Borst, J.; Neefjes, J. J.; Ovaa, H. Profiling proteasome activity in tissue with fluorescent probes. Mol. Pharm. 2007, 4, 739-748
192. Dantuma, N. P.; Lindsten, K.; Glas, R.; Jellne, M.; Masucci, M. G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat. Biotechnol. 2000, 18, 538-543
193. Lindsten, K.; Menendez-Beito, V.; Masicci, M. G.; Dantuma, N. P. A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol. 2003, 21, 897-902
194. Luker, G. D.; Pica, C. M.; Song, J.; Luker, K. E.; Piwnica-worms, D. Imaging 26S proteasome activity and inhibition in living mice. Nat. Med. 2003, 9, 969-973
195. Rogers, A.; Joe, Y.; Manshouri, T.; Dey, A.; Jilani, I.; Giles, F.; Estey, E.; Freireich, E. J.; Keating, M.; Kantarjian, H.; Albitar, M. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood 2004, 103, 2799-2801
196. Manshouri, T.; Do, K. A.; Wang, X.; Giles, F. J.; O'Brien, S. M.; Saffer, H.; Thomas, D.; Jilani, I.; Kantarjian, H. M.; Keating, M. J.; A. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003, 101, 2507-2513
197. Giles, F. J.; Albitar, M. Plasma-based testing as a new paradigm for clinical testing in hematologic diseases. Expert Rev. Mol. Diagn. 2007, 7, 615-623
198. Yeh, C. H.; Tseng, R.; Albitar, M. Plasma-based detection of clonality in lymphoid malignancies. Eur. J. Haematol. 2009, 82, 450-453
199. Ma, W.; Kantarjian, H.; Zhang, X.; Sun, W.; Buller, A. M.; Jilani, I.; Schwartz, J. G.; Giles, F.; Albitar, M. Higher detection rate of JAK2 mutation using plasma. Blood 2008, 111, 3906-3907
200. Ma, W.; Kantarjian, H.; O'Brien, S.; Jilani, I.; Zhang, X.; Estrov, Z.; Ferrajoli, A.; Keating, M.; Giles, F.; A. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 2008, 112, 1306-1312
201. Hamlin, P. A.; Aghajanian, C.; Younes, A.; Hong, D. S.; Palladino, M. A.; Longenecker, A. M.; Lloyd, G. K.; Hannah, A. L.; Spear, M. A.; Kurzrock, R. First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052. J. Clin. Oncol. 2009, 27, 15s, 3516
202. Millward, M.; Spear, M. A.; Townsend, A.; Sweeney, C.; Sukumaran, S.; Longenecker, A.; Palladino, M. A.; Lloyd, G. K.; Neuteboom, S. T. C.; Price, T. Clinical trial combining proteasome (NPI-0052) and HDAC (vorinostat) inhibition in melanoma, pancreatic and lung cancer. Mol. Cancer Ther. 2009, 8, Abstr. 107
203. Moreau, P.; Coiteux, V.; Hulin, C.; Leleu, X.; van de Velde, H.; Acharya, M.; Harousseau, J. L. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008, 93, 1908-1911
204. Vij, R.; Siegel, D. S.; Kaufman, J. L.; Jakubowiak, A. J.; Stewart, A. K.; Jagannath, S.; Kukreti, V.; Le, M. H.; Bennett, M. K.; Wang, M. Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). J. Clin. Oncol. 2010, 28, 7s, 8000
205. Piva, R.; Ruggeri, B.; Williams, M.; Costa, G.; Tamagno, I.; Ferrero, D.; Giai, V.; Coscia, M.; Peola, S.; Massaia, M.; Pezzoni, G.; Allievi, C.; Pescalli, N.; Cassin, M.; di Giovine, S.; Nicoli, P.; de Feudis, P.; Strepponi, I.; Roato, I.; Ferracini, R.; Bussolati, B.; Camussi, G.; Jones-Bolin, S.; Hunter, K.; Zhao, H.; Neri, A.; Palumbo, A.; Berkers, C.; Ovaa, H.; Bernareggi, A.; Inghirami, G. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008, 111, 2765-2775
206. Kupperman, E.; Lee, E. C.; Cao, Y.; Bannerman, B.; Fitzgerald, M.; Berger, A.; Yu, J.; Yang, Y.; Hales, P.; Bruzzese, F.; Liu, J.; Blank, J.; Garcia, K.; Tsu, C.; Dick, L.; Fleming, P.; Yu, L.; Manfredi, M.; Rolfe, M.; Bolen, J. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010, 70, 1970-1980
207. Zhou, H. J.; Aujay, M. A.; Bennett, M. K.; Dajee, M.; Demo, S. D.; Fang, Y.; Ho, M. N.; Jiang, J.; Kirk, C. J.; Laidig, G. J.; Lewis, E. R.; Lu, Y.; Muchamuel, T.; Parlati, F.; Ring, E.; Shenk, K. D.; Shields, J.; Shwonek, P. J.; Stanton, T.; Sun, C. M.; Sylvain, C.; Woo, T. M.; Yang, J. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem. 2009, 52, 3028-3038.